Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.

about

Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q39226762

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Investigational drugs targetin ...... of non-small cell lung cancer.

@en

Investigational drugs targetin ...... of non-small cell lung cancer.

@nl

type

Item

label

Investigational drugs targetin ...... of non-small cell lung cancer.

@en

Investigational drugs targetin ...... of non-small cell lung cancer.

@nl

prefLabel

Investigational drugs targetin ...... of non-small cell lung cancer.

@en

Investigational drugs targetin ...... of non-small cell lung cancer.

@nl

P1476

Investigational drugs targetin ...... of non-small cell lung cancer.

@en

P2093

Erika Rijavec

http://www.w3.org/2001/XMLSchema#string

Federica Biello

http://www.w3.org/2001/XMLSchema#string

Giulia Barletta

http://www.w3.org/2001/XMLSchema#string

Simona Boccardo

http://www.w3.org/2001/XMLSchema#string

P2860

Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor

FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer.

Identification of a new fibroblast growth factor receptor, FGFR5

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.

Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.

Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.

Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer.

P304

551-561

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2017.1316714

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28388262

http://www.w3.org/2001/XMLSchema#string